Beasley Allen attorney Danielle Ward Mason has been appointed to the Plaintiffs’ Steering Committee (PSC) for consolidated multidistrict litigation (MDL) pending in New Jersey federal court against Johnson & Johnson’s Janssen Pharmaceuticals over claims that the company’s type 2 diabetes drug Invokana causes kidney damage and diabetic ketoacidosis. Those suing Janssen allege that the drug company inadequately tested Invokana and failed to warn doctors or patients of Invokana side effects.
The Judicial Panel on Multidistrict Litigation consolidated 55 lawsuits from across the country and appointed U.S. District Judge Brian R. Martinotti to preside over the MDL. An MDL is a type of legal preceeding designed to help federal courts efficiently manage several related cases filed in different jurisdictions. To be eligible for an MDL, a group of lawsuits must involve one or more common questions of fact.
For the Invokana MDL, plaintiffs allege the diabetes drug caused them to suffer kidney damage, including acute kidney injury (AKI), and kidney failure, resulting in some cases in hospitalization and dialysis.
Plaintiffs also allege use of Invokana can lead to diabetic ketoacidosis (DKA), a serious condition in which too much acid builds up in the blood. Complications related to DKA include difficulty breathing, nausea, vomiting, abdominal pain, confusion and unusual fatigue or sleepiness. If left untreated, DKA can lead to diabetic coma or death. In a Diabetes Care Study published in September 2015, Invokana was associated with a much higher DKA risk than other diabetes medications in its class.
Ward has been with Beasley Allen since 2009 and is the firm’s lead attorney for Invokana litigation. In 2015, she was became the first African-American woman at the firm to be named Principal attorney. In addition to her work with Invokana, she is a member of the talcum powder ovarian cancer litigation team.
Source: Beasley Allen Law Firm